A diet enriched with red sorghum flaked biscuits, compared to a diet containing white wheat flaked biscuits, does not enhance the effectiveness of an energy-restricted meal plan in overweight and mildly obese adults

Anita Stefoska-Needham  
University of Wollongong, an442@uowmail.edu.au

Eleanor J. Beck  
University of Wollongong, eleanor@uow.edu.au

Stuart K. Johnson  
Curtin University

Marijka Batterham  
University of Wollongong, marijka@uow.edu.au

Ross Grant  
University of New South Wales, University of Sydney

Publication Details  
See next page for additional authors
A diet enriched with red sorghum flaked biscuits, compared to a diet containing white wheat flaked biscuits, does not enhance the effectiveness of an energy-restricted meal plan in overweight and mildly obese adults

Abstract
Objectives: Whole grain sorghum is a promising ingredient in foods, especially those targeting satiety and weight control. This study aimed to test weight loss effects of a whole grain red sorghum product incorporated into an energy-restricted diet.

Methods: Sixty subjects (46 females) were randomized to either a sorghum (intervention) or white wheat (control) group, receiving 45 g of flaked cereal biscuits to include daily in their prescribed diets for 12 weeks. Primary outcome was weight loss. Secondary outcomes included plasma glucose, glycosylated hemoglobin (HbA1c), insulin, total cholesterol, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), triacylglycerides (TAG), interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), and total antioxidant capacity (TAC; measured at 0 and 12 weeks).

Results: After 12 weeks, there were no significant differences in weight loss or any clinical variables between a wheat control and sorghum cereal group in an energy-restricted diet. Equivalent amounts of weight were lost (p = 0.369) in both groups, and the majority of clinical indices such as fasting glucose, insulin, cholesterol, and key inflammatory biomarkers showed significant beneficial changes over time (p < 0.05).

Conclusions: Although both groups experienced significant weight loss and general improvement in a number of clinical measures, no effects appeared specifically related to sorghum consumption. Further clinical trials are necessary to establish an evidence base for weight loss effects from chronic sorghum intake. Sorghum represents a viable, gluten-free grain alternative in the formulation of novel food products.

Keywords
does, wheat, white, containing, compared, biscuits, flaked, sorghum, red, enriched, diet, mildly, overweight, plan, meal, adults, energy-restricted, obese, effectiveness, enhance, not

Disciplines
Medicine and Health Sciences

Publication Details

Authors
Anita Stefoska-Needham, Eleanor J. Beck, Stuart K. Johnson, Marijka Batterham, Ross Grant, John F. Ashton, and Linda C. Tapsell

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1018
A diet enriched with red sorghum flaked biscuits, compared to a diet containing white wheat flaked biscuits, does not enhance the effectiveness of an energy-restricted meal plan in overweight and mildly obese adults

Authors: Anita Stefoska-Needham¹ (MSc), Eleanor J. Beck¹ (PhD), Stuart K. Johnson² (PhD), Marijka J. Batterham³ (PhD), Ross Grant⁴ (PhD), John Ashton⁵ (PhD), Linda C. Tapsell¹ (PhD).

¹ School of Medicine, Illawarra Health & Medical Research Institute, University of Wollongong, NSW, 2522, Australia.
² School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA, 6845, Australia.
³ Statistical Consulting Centre, National Institute for Applied Statistics Research Australia, University of Wollongong, NSW, 2522, Australia.
⁴ School of Medical Sciences, University of NSW, Sydney, NSW, 2052, Australia; Sydney Adventist Hospital Clinical School, University of Sydney, Sydney, NSW, 2006, Australia.
⁵ Sanitarium Development and Innovation, Cooranbong, NSW, 2265, Australia.

Corresponding author (including reprint requests):
Anita Stefoska-Needham
School of Medicine, Illawarra Health & Medical Research Institute, University of Wollongong, Wollongong, 2522 Australia.
T: +61 458850088; an442@uowmail.edu.au

Funding and conflict of interest disclosures:
This project was supported by The Australian Research Council in the form of a Linkage Project grant (LP10020012) and a collaboration agreement between the University of Wollongong (UOW) and the Australian Health and Nutrition Association. Authors declare no conflict of interest.

Running title:
Effects of a sorghum-enriched diet in humans

Key words:
Sorghum, Whole grain sorghum, Health, Weight management, Satiety, Flaked cereal biscuit

Abbreviations:
HbA1c, Glycosylated hemoglobin; TC, Total cholesterol; HDL-C, High density lipoprotein cholesterol; LDL-C, Low density lipoprotein cholesterol; TAG, Triacylglycerides; IL1β, Interleukin 1β; IL-6, Interleukin 6; IL-8, Interleukin 8; TNFα, Tumor necrosis factor alpha; hsCRP, High sensitivity c-reactive peptide; TAC, Total antioxidant capacity
ABSTRACT

Objectives: Whole grain sorghum is a promising ingredient in foods, especially those targeting satiety and weight control. This study aimed to test weight loss effects of a whole grain red sorghum product incorporated into an energy-restricted diet.

Methods: Sixty subjects (46 females) were randomized to either a sorghum (intervention) or white wheat (control) group, receiving 45g of flaked cereal biscuits to include daily in their prescribed diets for 12 weeks. Primary outcome was weight-loss. Secondary outcomes included plasma glucose, HbA1c, insulin, total cholesterol, HDL-C, LDL-C, TAG, IL1β, IL-6, IL-8, TNFα, hsCRP, TAC (measured at 0 and 12 weeks).

Results: After 12 weeks, there were no significant differences in weight loss or any clinical variables between a wheat control and sorghum cereal group in an energy-restricted diet. Equivalent amounts of weight were lost (p=0.369) in both groups and the majority of clinical indices such as fasting glucose, insulin, cholesterol and key inflammatory biomarkers showed significant beneficial changes over time (p<0.05).

Conclusions: Although both groups experienced significant weight loss and general improvement in a number of clinical measures, no effects appeared specifically related to sorghum consumption. Further clinical trials are necessary to establish an evidence base for weight loss effects from chronic sorghum intake. Sorghum represents a viable, gluten-free grain alternative in the formulation of novel food products.
INTRODUCTION

Dietary patterns rich in plant foods are positively associated with indicators of health [1]. These diets include a variety of foods and food components that have beneficial effects on disease markers and health outcomes, including body weight regulation, important in the prevention of chronic disease [2]. Characteristically high in dietary fiber, phytonutrients and lower in total energy value, the purported benefits of these diets may be attributed to mechanisms involving satiety and appetite regulation, glycemic and insulinemic control, lipid regulation, and reduced oxidative stress and inflammatory processes.

Whole grain cereal foods constitute an important component of plant-based diets. They are a source of dietary fiber and contain an array of bioactive compounds, including polyphenols. Sorghum (*Sorghum bicolor* L. Moench) is an example of a gluten-free whole grain cereal, with a reputation for being satiating [3]. Not surprisingly, sorghum is gaining attention from food manufacturers and researchers as a suitable ingredient in foods targeting satiety to assist with longer-term weight management, particularly in populations where obesity-related diseases are prevalent and food is ubiquitous [4]. Sorghum’s appeal is further enhanced by its potential as a sustainable crop with numerous agronomic advantages including low production costs, high temperature tolerance and adaptability to drought [5, 6].

Sorghum grain is mostly composed of starch, with levels reported as high as 71% of dry whole grain weight in some cultivars [7]. Sorghum starch granules are entangled in a strong protein matrix in the corneous endosperm (hard outer region) of the grain kernel, which may impede the actions of carbohydrate-hydrolyzing enzymes, resulting in reduced *in vitro* starch digestibility [8]. The starch granules exist in a more open structure in the floury endosperm of the grain kernel. More commonly utilized *hard* wheat is also characterized by a higher ratio of
corneous to floury endosperm, in which the starch granules are more tightly bound to proteins. The lower starch digestibility may also be a consequence of interactions with the cell wall material and polyphenolic compounds such as flavonoids (namely anthocyanins) and condensed tannins [9, 10]. A variety of sorghum-based foods have been confirmed to deliver slowly digestible starches (SDS) [11, 12], which have been associated with lower glucose responses, and in some cases lower glycemic index (GI) [13]. Together with dietary and resistant starch, this array of qualities may result in enhanced satiety through which sorghum grain components may play a role in longer-term weight management and protection against obesity-related chronic diseases [5]. To date, indications for such effects have predominantly come from in-vitro [11,13] and animal studies [14, 15]. Our group has previously conducted the only clinical trial investigating satiety mechanisms relating to sorghum grain consumption in humans [16]. Using a crossover design in 20 male and 20 females subjects, three different types of sorghum flaked whole grain cereal biscuits (made from red, white or brown grained sorghum varieties and differing in polyphenolic content) were shown to extend acute subjective satiety sensations and increase satiety-enhancing gut hormones (GLP-1 and GIP and PYY in males) to a greater extent than a wheat control over a 4-hour period (p<0.05), although food intake at a second meal was not altered. The flaked biscuits made from red sorghum grain, a variety rich in anthocyanin flavonoids, elicited the greatest overall satiety-enhancing responses. We were unable to explain the responses in terms of the dietary fiber or the starch contents of the biscuits, but overall differences in polyphenol contents may have assisted the satiety responses.

While these initial acute satiety results were promising, longer-term effects on body weight and chronic disease biomarkers are the main target for providing evidence of health benefits. The present paper describes a 3-month randomized controlled dietary intervention trial,
designed to test effects of whole grain red sorghum included in an energy-restricted meal plan. The primary outcome was weight loss. Secondary outcomes were biochemical measures linked with change in body weight, such as glucose, insulin, cholesterol and a number of anti-inflammatory/oxidative stress markers, as well as subjective satiety measures. We hypothesized that (1) subjects receiving foods made from whole grain sorghum would lose more weight than subjects receiving control foods (wheat-based); (2) weight loss would be accompanied by changes in metabolic disease risk factors, which may be anticipated given the high polyphenolic content of the sorghum.

METHODS AND MATERIALS

Subjects and recruitment

This study was a 3-month, double-blinded, parallel, randomized controlled trial with a total of 60 subjects, 46 females and 14 males. There were two arms to the study: sorghum intervention and wheat control, with both groups receiving advice on an energy-restricted diet from an Accredited Practising Dietitian. All subjects were provided with cereal products, in the form of flaked breakfast biscuits, to include in their diets. The target sample size of 30 subjects per group was based on previous human intervention studies incorporating cereal/high fiber foods into hypo-caloric diets [17-19]. Difference in weight loss between groups was used as the primary outcome measure to establish power for the study. To observe a two-kilogram weight difference between groups, at a power of 80% and to be significantly different at level of α 0.05, 26 subjects would be required per group. Therefore, setting the recruitment target at 30 subjects per group would account for an approximate dropout rate of 15%. Eligible subjects (aged 18–65 years, BMI range from 25–35 kg/m²) were sought through paid media advertisements and institutional emails. Subjects with serious illness including diabetes, with known food allergies, and those taking appetite-altering medications
were excluded from the study. Restrictive eaters (identified using the Three Factor Eating Questionnaire by Stunkard & Messick [20]) and subjects who were smokers, were pregnant, breastfeeding and post-menopausal were also excluded. All procedures were approved by the University of Wollongong, Human Research Ethics Committee (approval number HE14/100). The trial was also prospectively registered with the Australian New Zealand Clinical Trials Registry (ACTRN12614000640606).

A total of 115 potential subjects expressed interest in the study of which 103 were contacted to undergo further preliminary screening via telephone (Figure 1). From this group, 80 people were eligible for further assessment in the form of a detailed screening questionnaire. This led to sixty-one people attending an interview to determine final eligibility with sixty subjects randomized into the two study groups by a researcher independent of the subject interface, stratified by sex, block randomized using STATA Version 12 and using the RALLOC command (StataCorp, 2011, College Station, Texas, USA). The researcher/dietitian and all subjects at the subject interface were blinded to the randomization. The subjects attended the clinical research trials unit (CRTU) at the University of Wollongong, Australia, on five occasions. The first visit included collection of background dietary data using a validated diet history interview [21] and instruction on the completion of a 3-day weighed food record. The subsequent visit included collection of fasting blood samples (baseline) and dietary education. Two follow-up dietary visits occurred at the 1-month and 2-month time-points, with collection of fasting blood samples at 3 months (final visit). All the subjects had their height, weight, percentage body fat (Tanita Scales Model no.TBF-662) and waist circumference recorded at each visit to the CRTU. Visual analogue scales (VAS) related to appetite [22] and food records were all completed at baseline, half-way through the study (at the 6-week point) and within the final week of the study. The Baecke Physical Activity Questionnaire [23] was
completed at baseline and at the completion of the study.

For the appetite VAS, the subjects recorded their appetite responses on individual forms at six different time-points throughout the day: immediately before each of the three main meals and 2 h after each of these meals but before their subsequent snack. The VAS consisted of a 100 mm horizontal line, anchored at each end with opposing responses (for example, "not at all hungry" and "never been more hungry"). The study participants were instructed to place a vertical mark on the line to correspond with their feelings and the subjective sensation was quantified by measuring the distance in millimeters from the left end of the line to the mark. All nutritional analysis was performed using FoodWorks 2007, version 5 (Xyris Software, Brisbane, QLD, Australia) with nutrient contents of study foods added as required.

**Dietary intervention**

For each subject, a basal metabolic energy requirement was calculated using the Mifflin-St Jeor equation where a BMI equal to 25 kg/m$^2$ was included [24]. A low activity factor (1.3) was chosen to estimate energy requirements (given the overweight sample with limited usual physical activity) and then this level was reduced by 20% to drive weight loss. Intervention diets were designed to control for all macronutrients with the only variation being the trial cereal products given, as described in Table 1. The sorghum intervention group received whole grain sorghum-based cereal biscuits and the whole wheat control group received wheat-based cereal biscuits, matched by serve size (3 biscuits) and therefore overall mass (45g per day). Wheat was chosen as the suitable food control because it has a different polyphenolic profile to red sorghum but has similar nutritional attributes and, from a behavioral perspective, wheat cereal products are readily interchangeable with sorghum breakfast cereal products.
**Test food products**

Organoleptically-acceptable test foods were manufactured in the form of ready-to-eat (RTE) flaked cereal biscuits, in a pilot processing plant by qualified cereal food technologists, as previously described by Stefoska-Needham et al. (2016). The sorghum flaked cereal biscuits were processed from red sorghum grain, variety Alpha, grown and supplied by Lochabar Enterprises Pty Ltd (Tara, QLD, Australia), with a small amount of added malt extract. A bleach test [25] confirmed the absence of tannins in the red sorghum grain. The wheat flaked cereal biscuits were made from non-cultivar-specific Australian Prime White (APW) hard wheat (grown in central New South Wales, Australia) and was supplied by Sanitarium Health and Wellbeing (Cooranbong, NSW, Australia). The whole wheat and whole sorghum grains were steamed and then passed between parallel smooth rollers producing whole grain flakes, reducing their thickness to 0.1 mm. The flakes were pressed together to form rectangular prism-shaped biscuits, which were subsequently toasted in an oven to reduce the moisture content and produce a shelf stable product [16]. This process differs from the shredded wheat process in that the wheat is not cut into strips at any stage.

The subjects were instructed to eat two cereal biscuits (30g) at breakfast and one biscuit (15g) at afternoon tea daily. The proximate, dietary fiber and energy content (on as is basis per 100g) (Table 2), polyphenolic (PP) content (mg GAE/g as is) (Table 3) and starch properties (per 100g as is) (Table 4) were previously reported by Stefoska-Needham et al., 2016). Analyses identified modest differences between the control and sorghum biscuits with respect to energy, macronutrients and dietary fiber (Table 2). Notably, both total and soluble fiber levels were higher in the whole wheat control compared to the sorghum biscuits, however the actual difference between biscuits was modest at 0.86g and 0.13g per 45g test serve,
respectively. Individual macronutrient levels were not controlled for because this study was
designed to test whole foods as consumed in real-life settings, hence the serve size rather than
specific components were matched. As expected, red sorghum biscuits had higher PP levels
compared to the control (Table 3), most likely due to high anthocyanin contents characteristic
of this sorghum variety [3]. Assessment of starch properties showed no difference in the
amount of total starch, rapidly digestible starch (RDS) and slowly SDS between biscuits, and
in particular the levels of SDS in each serve classified as high (Table 4).

Clinical indices
Fasting blood samples were collected at 0 and 3 months into clot gel tubes, centrifuged and
stored at -80° Celsius until analysis could be completed according to standard protocols for
glucose, insulin, total cholesterol, high-density lipoprotein (HDL-c), low-density lipoprotein
(LDL-c), triacylglycerides (TAG) and high-sensitivity c-reactive peptide (hsCRP) at Sydney
Adventist Hospital Pathology (Wahroonga, NSW, Australia). Glycosylated hemoglobin
(HbA1c) was performed by Southern Pathology (Wollongong, NSW, Australia) after samples
were collected into tubes containing potassium EDTA and stored at 4° Celsius until analysis
was conducted. Additional markers for inflammation and oxidative stress, Interleukin 1β (IL1β),
Interleukin 6 (IL-6), Interleukin 8 (IL-8), tumor necrosis factor alpha (TNFα) and
total antioxidant capacity (TAC) were performed by the Australasian Research Institute,
(Sydney Adventist Hospital, Wahroonga, NSW, Australia) according to established protocols.

Statistical analysis
Data for all anthropometry, blood analysis, VAS measurements and dietary intake were
entered into SPSS for windows, version 21.0 (IBM SPSS 21.0, IBM Corporation, Armonk,
NY, USA). Repeated measures ANOVA (RMANOVA) using the general linear model with
group (control, sorghum) as the between subjects factor, was used to identify primary changes in each parameter over time and also differences between the groups. Post hoc analysis using Bonferroni adjustments was reviewed to detect specific differences between the control and intervention groups. Regression analysis was used to identify correlations between group anthropometric and biochemical indices.

RESULTS

Baseline data

There were twenty-six subjects in the sorghum intervention group (after four subjects withdrew) and thirty subjects in the control group (Figure 1). Reasons provided for their withdrawal were: relocation, commencement of a contraindicated medication and the lack of motivation to adhere to an energy-restricted meal plan. For the final analysis, fifty-six subjects were included, although numbers in each calculation varied because some subjects did not complete all forms (food records or VAS). There were no significant differences between group anthropometric, dietary and metabolic measures at baseline (Table 5), except for a slightly lower protein intake in the sorghum group. Baseline energy intakes seemed low, suggesting under-reporting by some subjects. Consequently at subsequent study visits, dietitians specifically addressed potential under-reporting with subjects when reviewing their individual food records. The subjects were mildly obese but overall they did not exhibit impaired glucose tolerance or insulin resistance [26], nor were they hyperlipidemic [27] or hypertensive [28].

Dietary intervention

The flaked cereal biscuits were consumed by subjects with no adverse reactions and dietary compliance was relatively high at approximately 85%, as determined by a manual count of
uneaten biscuits upon study completion. Food record analysis indicated no significant
difference between the groups for protein, carbohydrate and fat intakes at any of the time-
points once the study commenced. Review of the overall dietary composition of baseline diets
compared with the 3-month end-point showed a significant decrease in percentage energy
from fat (p<0.001), as well as saturated fat (p<0.001). Percentage energy from protein and
carbohydrate was not altered over time (Table 6).

Compliance with a weight reduction meal plan was identified by overall weight loss and
energy reduction reported in the food records. Total energy intake was significantly lower at
the mid-point (mean 7136 (SD 2164) kJ) and the end-point (mean 6880 (SD 1815) kJ)
(p<0.001) of the trial compared with the baseline (mean 8742 (SD 2656) kJ), using
RMANOVA with treatment as the between-group effect and time as the within-subject
variant. The lack of an interaction effect over time (p=0.671) suggests that there were no
differences between groups in energy intake over time. There were no significant differences
in activity scores between the groups at any time-point, indicating that changes in physical
activity were not a factor in influencing overall results.

**Clinical indices**

The majority of the anthropometric and biochemical indices changed over 3-months;
however, there were no significant differences between the groups for any of the measured
clinical parameters over this time (Table 7). The average weight loss for the study sample was
significant at 5.3 kg (p<0.001) (or 6.1% of baseline body weight) over the 3-month
intervention. The mean weight changes ranged from a 2.1kg gain to a 14.7 kg loss, however
weight loss was not significantly different between the groups (p=0.369). Waist
measurements and percentage body fat decreased significantly compared to baseline
Regression analysis indicated that weight loss significantly predicted waist change (p<0.001) and percentage body fat (p<0.001). As expected, these predictions were strong ($R^2 = 0.389$ and $R^2 = 0.615$). Fasting blood glucose (p<0.001) and fasting insulin levels decreased over 3 months (p<0.001) but HbA1c did not change. No between groups differences were identified for any of these clinical indices (Table 7). The inflammatory cytokines IL1β, IL-6 and IL-8, decreased significantly compared to baseline (p<0.001), as did TNFα (p<0.001). TAC levels also decreased significantly compared to baseline (p<0.001). There were no significant changes over time in hsCRP levels. The reduction in total cholesterol was not significantly different between the groups, with mean decreases of 0.3 (SD 0.6) mmol/l for the sorghum group and 0.5 (SD 0.7) mmol/l for the control. There was a significant decrease in total cholesterol over 3 months for all subjects (p<0.001), as well as significant decreases in HDL-c (p<0.001), LDL-c (p<0.05) and TAG (p<0.001) levels over this time.

**Subjective satiety**

VAS results were reviewed for the six daily time-points at 0, 6 and 12 weeks to compare any differences that may have existed between the control and test groups (RMANOVA). No significant differences were identified, demonstrating that all individuals reported similar feelings of hunger/fullness at the same test points (data not shown).

**DISCUSSION**

As a consequence of the dietary intervention, a reduction in energy intake was achieved in the overweight study sample. The reduced energy intake in both groups was an effective driver of weight loss over the 3-month period. Regardless of the diet subjects followed, they lost weight and experienced beneficial changes in waist circumference, fasting glucose, fasting insulin, lipids and inflammatory markers. If maintained over time, the mean weight loss of
6.1% and reduced waist circumference (10.9 (SD 5.4) cm) for the study sample, could
decrease risk of insulin resistance, impaired glucose tolerance and dyslipidemias [29], as well
as lower the incidence of developing type 2 diabetes [30].

The present study was not able to confirm differentiating effects of sorghum grain
consumption on weight loss in an energy-restricted diet over 12 weeks where only the test
foods were different. This design is necessary, however, for rigorous testing of individual
foods where other dietary confounders are cancelled out. Despite a previous acute satiety
study with promising results [16], the present study showed that differences in meal satiety
do not necessarily translate to weight reduction differences in the longer term. Bearing in
mind that the energy restriction of the total diet was the same for both groups, subjects
receiving foods made from sorghum included in the dietary advice, did not lose more weight
than the subjects receiving control foods and similar overall dietary advice. Thus, the meal-
based satiety-enhancing mechanisms postulated to involve sorghum polyphenols did not have
an enhancing effect on body weight changes over 3 months, nor on overall reduction in
metabolic disease risk factors. Previous research conducted by our group has also shown that
where both the control and intervention diets focus on healthy eating patterns and control for
energy intakes, a difference in weight loss is not seen [31]. Ostensibly this is because weight
loss is dependent on control of energy intake and we matched the percentage energy
reduction in both arms. Typically also, no differences are seen when structured dietary advice
to both the control and intervention groups is provided [32], as was the case in the present
study. However, differences in other risk factor variables (affected by dietary attributes other
than total energy, such as dietary fat [33, 34] have been observed. Given our assumption that
a higher polyphenol intake from sorghum may have had similar effects, the study design was
appropriate, but we may now need to look to other potential synergistic components of the
diet, or a higher dose to pursue our hypothesis further.

The lack of differences between groups in changes in lipid levels was not consistent with
another study investigating the effects of consuming sorghum foods on serum lipid levels
[35]. In this study, a significant reduction (p<0.05) in total cholesterol, TAG and HDL-c was
observed in 10 males and 6 females after daily consumption of 100 g of unrefined sorghum in
the form of pancakes over 3 weeks. However, this study used a small sample size (with low
statistical power), reducing the likelihood that a statistically significant result reflects a true
effect. Further, the content of subjects’ background diets was not adequately reported, making
assessment of dietary confounders and final conclusions difficult. Overall, these results are
ambiguous hence more human evidence for lipid effects in relation to sorghum consumption
is warranted, and may be more relevant where weight loss inducing diets are not prescribed so
as to discern lipid lowering effects independent of weight loss.

A further strength of the present study was that we addressed the polyphenolic composition of
the test foods. From a physiological perspective, we considered the results of a recent
randomized, controlled, crossover human study, involving 22 healthy adults, assessing the
acute effects of consuming pasta containing red or white wholegrain sorghum flour (30%
sorghum, 70% semolina) on plasma total polyphenols, TAC and oxidative stress markers
compared to a wheat control made from 100% semolina [36]. Pasta containing red wholegrain
sorghum flour (RSP), but not white sorghum flour, enhanced antioxidant status and improved
markers of oxidative stress in healthy subjects (p<0.001). The increase in plasma polyphenols
by the RSP meal was attributed to its higher content of polyphenols. In the present study,
despite significant differences in the levels of polyphenols and TAC between the test food
products, we were not able to detect differences in the levels of inflammatory biomarkers and plasma TAC between the sorghum intervention and wheat control groups (Table 3). The reasons are not clear as to why the TAC levels unexpectedly decreased over time even though the inflammatory markers showed significant improvement. While standard protocols were followed and precautions taken, possible oxidation of blood samples during preparation or storage, cannot be ruled out [37]. Furthermore it may be that the effects of ingesting sorghum grain components are short-lived and subtle, hence the positive outcomes observed in acute studies may not translate to whole of diet studies conducted over a number of months.

The lack of differences in subjective satiety scores was perhaps expected. VAS are validated for use in highly controlled situations [22], such as acute meal test studies. We justified the inclusion of VAS to enable a possible link between reported ratings in this study and those of our previous acute satiety study [16], though realistically, the small differences from month to month in the present study were unlikely to be captured accurately by the subjects using the VAS tool. An alternative appetite questionnaire, validated for use in free-living conditions [38], may have been more informative.

Separating out the effects of individual components within a food, in this case the flaked cereal biscuit matrix, is difficult within a human intervention trial. To this end, a key strength of the present study is the comprehensive characterization of the physico-chemical properties of the test foods used in the intervention diets, assisting researchers to link clinical effects to components within the food. In our previous work [16], determination of polyphenolic compounds, dietary fiber, profiling of starch contents and proximate analyses of the RTE sorghum flaked biscuits, enabled us to hypothesize that the polyphenolic compounds played a role in observed acute satiety effects that would drive weight loss in the present RCT. Overall,
the lack of positive results should not infer that sorghum is not a beneficial ingredient in cereal foods, as subjects consumed the foods successfully, lost weight, decreased their serum cholesterol and showed other positive outcomes related to metabolic health. The whole grain sorghum product was as effective as the whole grain wheat product in the present study. Sorghum, like other whole grain cereals, delivers beneficial, health-promoting components and properties (such as antioxidants, dietary fiber, SDS and valuable energy) when it is consumed as part of a healthy food within a healthy diet.

As with most human dietary intervention trials, there are a number of confounding variables in the present study that require some consideration. Firstly, the trial was only a 3-month intervention and this period of time may not be long enough to detect differences between the subjects’ compliance with an energy restricted diet and the actual effects of the dietary intervention. It has been shown that subjects who reported greater compliance with a weight loss protocol lost more weight regardless of the dietary intervention [39], suggesting that strategies to increase adherence may be more important than the actual composition of the diet. Validated “measures of adherence” to enhance compliance to dietary advice in the context of clinical interventions would therefore be useful in future studies [40].

Secondly, the present study included similar test food products for both the intervention group and the control group, which only varied in the source of whole grain (sorghum versus wheat). The effect of individual grain components within the cereal biscuits, even if positive, are likely to be relatively small and hence showing a statistical difference between the groups would be difficult, especially over 3 months. Significant differences between the treatment and control groups may have been detected if the whole wheat control biscuits were lower in dietary fiber and higher in RDS compared to the sorghum biscuits. Further, instructing
subjects to eat food products at both breakfast and at afternoon tea as part of the compliance criteria for the dietary intervention protocols, may have actually increased overall energy consumption at times when the subjects might otherwise have chosen not to eat or to eat less in either arm of the study.

Thirdly, it is difficult to control the dietary intake of human subjects. Although food records and discussions with subjects during study interviews indicated high compliance with consumption of test products, the subjects were less compliant with the energy restriction as evidenced by the lower-than-predicted weight loss. All four subjects that withdrew from the study were from the intervention group, which could infer the greatest difficulty with compliance, but this is less likely given the reasons provided for their withdrawal. Lastly, large standard deviations existed within all the analyzed datasets, limiting the ability to detect significant results. The large standard deviations indicated that individual fluctuations are more varied than any overall effect of sorghum intake.

**CONCLUSION**

Although both groups experienced significant weight loss and general improvement in all clinical measures such as fasting glucose, insulin, cholesterol and key inflammatory biomarkers, no effects appeared specifically related to sorghum consumption. Overall, there were no discernable differences between an energy-restricted diet containing a wheat-based cereal food and that containing a sorghum-based cereal food. With a longer intervention and greater exposure to the test foods, some differences might have been detected, as subtle effects of components in the cereal foods would become more prominent. Nevertheless, the consumption of sorghum flaked breakfast cereal biscuits in the context of an energy-restricted diet is not deleterious in overweight and mildly obese individuals, and in fact represents a
viable gluten-free alternative to wheat in food products.

ACKNOWLEDGEMENTS

We are grateful to the management and staff of the Illawarra Health & Medical Research Institute for the opportunity to conduct this study in their clinical trials unit and for their assistance with collection of blood samples. Thank you also to Monique de Abreu, Kayla Thornhill, Emma Goddard, Ryan Platt and Kurt Morton (University of Wollongong dietetics students) for assistance with data entry. A heart-felt thank you to all the study participants for their time and commitment to this important research.

AUTHORSHIP

AS-N, EJB, JA, RG and LCT designed the study. AS-N conducted the study, analyzed dietary and biochemical data, and performed statistical analyses (guided by MJB). Biscuits were formulated by the industry sponsor, led by JA. AS-N wrote the first draft of the manuscript and all authors read, edited, and approved the final manuscript. AS-N had primary responsibility for the final content.
REFERENCES


Table 1 - Dietary prescription (totaling 5,500kJ) for a typical participant

<table>
<thead>
<tr>
<th>Food Group</th>
<th>Portion or serve size</th>
<th>Number of serves / day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control or intervention products</td>
<td>1 flaked cereal biscuit = 15g</td>
<td>3 (2 biscuits at breakfast and 1 at afternoon tea)</td>
</tr>
<tr>
<td>Breads/cereal/starchy vegetables</td>
<td>1 slice bread or 1/2 cup cooked pasta or 1/3 cup cooked rice or 1 small potato</td>
<td>4</td>
</tr>
<tr>
<td>Other vegetables</td>
<td>1/2 cup cooked or 1 cup raw</td>
<td>2.5 cooked or 5 raw</td>
</tr>
<tr>
<td>Fruit</td>
<td>1 piece fresh or 3/4 cup canned and drained</td>
<td>2</td>
</tr>
<tr>
<td>Milk / alternatives</td>
<td>150ml light or 200ml skim, 100g low-fat yoghurt</td>
<td>2-3</td>
</tr>
<tr>
<td>Meat / alternatives</td>
<td>30g meat or 50g fish or 20g low fat cheese</td>
<td>3-4</td>
</tr>
<tr>
<td>Fats</td>
<td>1 tsp. oil or margarine or 1 tbsp. avocado</td>
<td>3-4</td>
</tr>
</tbody>
</table>
Table 2 - Proximate and dietary fiber composition and energy content of flaked breakfast cereals, adapted from Stefoska-Needham et al. (2016) 1,2

<table>
<thead>
<tr>
<th>Flaked breakfast cereal type</th>
<th>Moisture (g/100g as is)</th>
<th>Protein (g/100g as is)</th>
<th>Fat (g/100g as is)</th>
<th>Ash 3</th>
<th>Total dietary fiber (g/100g as is)</th>
<th>Total available carbohydrates 4 (g/100g as is)</th>
<th>Energy content (kJ/100g as is)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheat control</td>
<td>6.6±0.0</td>
<td>13.7±0.2 b</td>
<td>1.7±0.0 a</td>
<td>1.6±0.0</td>
<td>9.6±0.1 b</td>
<td>66.9±0.1 a</td>
<td>1508±1 a</td>
</tr>
<tr>
<td>Sorghum (red)</td>
<td>6.6±0.0</td>
<td>9.4±0.1 a</td>
<td>2.9±0.1 b</td>
<td>1.6±0.0</td>
<td>7.7±0.0 a</td>
<td>71.9±0.1 a</td>
<td>1550±0 b</td>
</tr>
</tbody>
</table>

1 Means (n=2) ± standard deviation
2 Values within a column with the same superscript letter denotes no significant difference (p>0.05)
3 Statistical comparison not possible as some replicates identical
4 Available carbohydrate calculated by difference
Table 3 - Free, bound and total phenolic content and antioxidant capacity of flaked breakfast cereals, adapted from Stefoska-Needham et al. (2016) ¹,²

<table>
<thead>
<tr>
<th>Flaked breakfast cereal type</th>
<th>Free PP (mg GAE/g as is)</th>
<th>Bound PP (mg GAE/g as is)</th>
<th>Total PP (mg GAE/g as is)</th>
<th>Free AC (µmolTE/g as is)</th>
<th>Bound AC (µmolTE/g as is)</th>
<th>Total antioxidant capacity (µmolTE/g as is)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheat control</td>
<td>0.71±0.01⁺</td>
<td>0.67±0.22⁺</td>
<td>1.37±0.21⁺</td>
<td>2.64±0.01⁺</td>
<td>2.67±0.01⁺</td>
<td>5.31±0.01⁺</td>
</tr>
<tr>
<td>Sorghum (red)</td>
<td>1.27±0.01ᵇ</td>
<td>1.00±0.11⁺</td>
<td>2.27±0.12ᵇ</td>
<td>11.25±0.57ᵇ</td>
<td>9.16±0.62ᵇ</td>
<td>20.40±1.18ᵇ</td>
</tr>
</tbody>
</table>

¹Means (n=2) ± standard deviation
²Values within a column with the same superscript letter denotes no significant difference (p>0.05)
PP, polyphenolic; AC, antioxidant capacity; GAE, Gallic acid equivalents; TE, Trolox equivalents
Table 4 - Starch properties of flaked breakfast cereals, adapted from Stefoska-Needham et al. (2016) ¹,²

<table>
<thead>
<tr>
<th>Flaked breakfast cereal type</th>
<th>Total starch ³ (g/100g as is)</th>
<th>Rapidly digested starch (g/100g dry starch)</th>
<th>Slowly digested starch (g/100g dry starch)</th>
<th>Resistant starch (g/100g dry starch)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheat control</td>
<td>54.2 ± 0.2 ³</td>
<td>31.9±1.6 ³</td>
<td>47.9±4.2 ³</td>
<td>20.2±3.9 ³</td>
</tr>
<tr>
<td>Sorghum (red)</td>
<td>57.7 ± 2.3 ³</td>
<td>31.9±4.2 ³</td>
<td>46.9±7.7 ³</td>
<td>21.2±3.6 ³</td>
</tr>
</tbody>
</table>

¹Means (n=2) ± standard deviation
²Values within a column with the same superscript letter denotes no significant difference (p>0.05)
³Total starch was determined using a Megazyme K-TSTA 09/14 Total Starch Kit (Bray, Ireland) which excludes low molecular weight starch hydrolysis/breakdown products that may have resulted during the manufacturing process
### Table 5 - Baseline characteristics of study subjects (means and standard deviations)

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>CONTROL</th>
<th>SORGHUM</th>
<th>DIFFERENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>48.6</td>
<td>48.1</td>
<td>0.859</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>86.1</td>
<td>87.1</td>
<td>0.732</td>
</tr>
<tr>
<td>BMI (kg/m^2)</td>
<td>31.6</td>
<td>31.2</td>
<td>0.632</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>105.3</td>
<td>102.5</td>
<td>0.311</td>
</tr>
<tr>
<td>Fat (%)</td>
<td>40.3</td>
<td>38.7</td>
<td>0.309</td>
</tr>
<tr>
<td>Fasting Blood glucose (mmol/L)</td>
<td>5.2</td>
<td>5.3</td>
<td>0.297</td>
</tr>
<tr>
<td>Fasting Insulin (mIU/L)</td>
<td>12.5</td>
<td>12.3</td>
<td>0.893</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.3</td>
<td>5.2</td>
<td>0.554</td>
</tr>
<tr>
<td>Total Cholesterol (mmol/L)</td>
<td>5.6</td>
<td>5.3</td>
<td>0.173</td>
</tr>
<tr>
<td>LDL-c (mmol/L)</td>
<td>3.5</td>
<td>3.2</td>
<td>0.193</td>
</tr>
<tr>
<td>HDL-c (mmol/L)</td>
<td>1.4</td>
<td>1.5</td>
<td>0.533</td>
</tr>
<tr>
<td>TAG (mmol/L)</td>
<td>1.6</td>
<td>1.3</td>
<td>0.155</td>
</tr>
<tr>
<td>IL1β (pg/ml)</td>
<td>0.9</td>
<td>0.9</td>
<td>0.841</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>1.5</td>
<td>0.8</td>
<td>0.052</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>6.2</td>
<td>5.2</td>
<td>0.096</td>
</tr>
<tr>
<td>TNFα (pg/ml)</td>
<td>2.9</td>
<td>3.2</td>
<td>0.483</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>2.7</td>
<td>2.4</td>
<td>0.662</td>
</tr>
<tr>
<td>TAC (mmol/L Trolox)</td>
<td>1.2</td>
<td>1.3</td>
<td>0.476</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>82.3</td>
<td>80.4</td>
<td>0.407</td>
</tr>
<tr>
<td>Systolic BP (mm Hg)</td>
<td>126.2</td>
<td>122.3</td>
<td>0.349</td>
</tr>
</tbody>
</table>
Table 6 - Energy and macronutrient intakes reported by subjects at baseline, mid-point and 3-months, with p-values for repeated measures ANOVA between control and sorghum groups (mean values and standard deviations)

<table>
<thead>
<tr>
<th>VARIABLE</th>
<th>BASELINE CONTROL</th>
<th>BASELINE SORGHUM</th>
<th>MID-POINT CONTROL</th>
<th>MID-POINT SORGHUM</th>
<th>3 MONTHS CONTROL</th>
<th>3 MONTHS SORGHUM</th>
<th>P-VALUES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>9274.0</td>
<td>2696.2</td>
<td>7897.3</td>
<td>2429.8</td>
<td>6752.8</td>
<td>2090.6</td>
<td>7082.0</td>
</tr>
<tr>
<td>Protein (g)</td>
<td>106.6</td>
<td>33.2</td>
<td>89.5</td>
<td>30.8</td>
<td>81.7</td>
<td>26.2</td>
<td>89.6</td>
</tr>
<tr>
<td>% E Protein</td>
<td>20.0</td>
<td>5.2</td>
<td>19.5</td>
<td>4.1</td>
<td>20.7</td>
<td>3.4</td>
<td>21.5</td>
</tr>
<tr>
<td>CHO (g)</td>
<td>234.6</td>
<td>84.5</td>
<td>190.6</td>
<td>60.7</td>
<td>177.9</td>
<td>56.8</td>
<td>183.2</td>
</tr>
<tr>
<td>% E CHO</td>
<td>39.9</td>
<td>5.1</td>
<td>39.1</td>
<td>7.09</td>
<td>42.6</td>
<td>6.3</td>
<td>41.5</td>
</tr>
<tr>
<td>Total Fat (g)</td>
<td>85.1</td>
<td>25.7</td>
<td>77.2</td>
<td>31.5</td>
<td>57.1</td>
<td>23.8</td>
<td>57.6</td>
</tr>
<tr>
<td>% E Total Fat</td>
<td>34.0</td>
<td>5.2</td>
<td>35.5</td>
<td>5.3</td>
<td>30.8</td>
<td>7.0</td>
<td>30.1</td>
</tr>
<tr>
<td>SFA (g)</td>
<td>34.3</td>
<td>12.4</td>
<td>29.8</td>
<td>14.3</td>
<td>20.3</td>
<td>8.6</td>
<td>20.4</td>
</tr>
<tr>
<td>% E SFA</td>
<td>13.7</td>
<td>3.2</td>
<td>13.6</td>
<td>3.3</td>
<td>11.0</td>
<td>3.0</td>
<td>10.7</td>
</tr>
<tr>
<td>PUFA (g)</td>
<td>12.7</td>
<td>5.3</td>
<td>12.9</td>
<td>6.6</td>
<td>9.1</td>
<td>4.7</td>
<td>9.5</td>
</tr>
<tr>
<td>% E PUFA</td>
<td>5.1</td>
<td>1.7</td>
<td>6.1</td>
<td>2.8</td>
<td>4.9</td>
<td>1.9</td>
<td>4.9</td>
</tr>
<tr>
<td>MUFA (g)</td>
<td>31.6</td>
<td>10.8</td>
<td>28.8</td>
<td>14.2</td>
<td>21.3</td>
<td>6.5</td>
<td>21.5</td>
</tr>
<tr>
<td>% E MUFA</td>
<td>12.6</td>
<td>2.8</td>
<td>13.1</td>
<td>3.2</td>
<td>11.3</td>
<td>4.0</td>
<td>11.3</td>
</tr>
<tr>
<td>Total Fiber (g)</td>
<td>26.3</td>
<td>9.0</td>
<td>25.6</td>
<td>9.5</td>
<td>24.1</td>
<td>9.2</td>
<td>27.2</td>
</tr>
</tbody>
</table>

E – energy; CHO – carbohydrate
* Significant values (p<0.05) were measured using repeated measures ANOVA
### Table 7 - Changes in anthropometric and biochemical indices over time between control and sorghum groups (mean values and standard deviations)

<table>
<thead>
<tr>
<th>INDICES</th>
<th>ALL GROUPS</th>
<th>CONTROL</th>
<th>SORGHUM</th>
<th>P-VALUES</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline data</td>
<td>Mean change</td>
<td>Baseline data</td>
<td>Mean change</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>86.6</td>
<td>11.6</td>
<td>-5.3</td>
<td>3.7</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.3</td>
<td>3.1</td>
<td>-1.9</td>
<td>1.4</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>104.2</td>
<td>10.9</td>
<td>-10.9</td>
<td>5.4</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>39.4</td>
<td>6.0</td>
<td>-2.1</td>
<td>2.3</td>
</tr>
<tr>
<td>Glucose (mmol/L)</td>
<td>5.26</td>
<td>0.50</td>
<td>-0.13</td>
<td>0.4</td>
</tr>
<tr>
<td>Insulin (mIU/L)</td>
<td>12.32</td>
<td>5.78</td>
<td>-2.86</td>
<td>3.3</td>
</tr>
<tr>
<td>HbA1c (mmol/L)</td>
<td>33.95</td>
<td>4.2</td>
<td>0.10</td>
<td>3.1</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.26</td>
<td>0.37</td>
<td>0.00</td>
<td>0.3</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>5.47</td>
<td>0.99</td>
<td>-0.40</td>
<td>0.7</td>
</tr>
<tr>
<td>HDL-c (mmol/L)</td>
<td>1.42</td>
<td>0.38</td>
<td>-0.07</td>
<td>0.2</td>
</tr>
<tr>
<td>LDL-c (mmol/L)</td>
<td>3.39</td>
<td>0.85</td>
<td>-0.15</td>
<td>0.5</td>
</tr>
<tr>
<td>TAG (mmol/L)</td>
<td>1.46</td>
<td>0.76</td>
<td>-0.40</td>
<td>0.6</td>
</tr>
<tr>
<td>IL-1β (pg/ml)</td>
<td>0.93</td>
<td>0.97</td>
<td>-0.15</td>
<td>0.4</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>1.19</td>
<td>1.29</td>
<td>-0.22</td>
<td>0.3</td>
</tr>
<tr>
<td>IL-8 (pg/ml)</td>
<td>5.73</td>
<td>2.46</td>
<td>-0.49</td>
<td>1.1</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>2.52</td>
<td>2.41</td>
<td>-0.28</td>
<td>1.8</td>
</tr>
<tr>
<td>TNFα (pg/ml)</td>
<td>3.06</td>
<td>1.23</td>
<td>-0.76</td>
<td>0.8</td>
</tr>
<tr>
<td>TAC (mmol/L Trolox)</td>
<td>1.26</td>
<td>0.18</td>
<td>-0.06</td>
<td>0.1</td>
</tr>
</tbody>
</table>

c – cholesterol; TAG – triacylglycerides; HbA1c – glycosylated hemoglobin; IL1β – Interleukin 1β; IL-6 – Interleukin 6; IL-8 – Interleukin 8; hsCRP – high sensitivity c-reactive protein; TNFα – tumour necrosis factor alpha; TAC – total antioxidant capacity

* Significant values were measured using repeated measures ANOVA
Fig. 1 Flow of participants through the trial

Assessed for eligibility (n 103) from 115 enquiries, (n 80) assessed further

Randomised at enrolment (n 60)

Excluded (n 20)
Not meeting criteria (n 16)
Refused to participate (n 2)
Other reasons (n 2)

Allocation

WHEAT CONTROL (n 30)
Received allocated intervention (n 30)

Lost to follow up (n 0)
Discontinued intervention (n 0)

Analysis

Analysed (n 30)
Excluded (n 0)

SORGHUM (n 30)
Received allocated intervention (n 30)

Lost to follow up (n 0)
Discontinued intervention (n 4): 1 relocated interstate, 2 unable to comply with dietary protocol, 1 commenced medication

Analysed (n 26)
Excluded (n 0)